Published in Kidney Int on July 02, 2008
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum (2012) 2.17
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol (2011) 1.51
Pathophysiology of ANCA-associated small vessel vasculitis. Curr Rheumatol Rep (2010) 1.17
T cells in ANCA-associated vasculitis: what can we learn from lesional versus circulating T cells? Arthritis Res Ther (2010) 1.02
B cell-mediated pathogenesis of ANCA-mediated vasculitis. Semin Immunopathol (2014) 0.85
Longitudinal studies of patients with ANCA vasculitis demonstrate concurrent reactivity to complementary PR3 protein segments cPR3m and cPR3C and with no reactivity to cPR3N. Autoimmunity (2010) 0.83
Overview of the Pathogenesis of ANCA-Associated Vasculitis. Kidney Dis (Basel) (2015) 0.82
Wegener's granulomatosis: a model of auto-antibodies in mucosal autoimmunity. Clin Immunol (2009) 0.81
Autoimmunity to the alpha 3 chain of type IV collagen in glomerulonephritis is triggered by 'autoantigen complementarity'. J Autoimmun (2015) 0.81
Reactivity against complementary proteinase-3 is not increased in patients with PR3-ANCA-associated vasculitis. PLoS One (2011) 0.80
Epigenetics and complementary proteins. Clin Exp Immunol (2011) 0.78
Identification of functional and expression polymorphisms associated with risk for anti-neutrophil cytoplasmic autoantibody-associated vasculitis. Arthritis Rheumatol (2016) 0.77
Pathogenesis and treatment of ANCA-associated vasculitis-a role for complement. Pediatr Nephrol (2016) 0.75
ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol (2017) 0.75
New allele frequency database: http://www.allelefrequencies.net. Tissue Antigens (2003) 3.30
Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med (2003) 2.85
MHC class II-restricted presentation of intracellular antigen. Cell (1991) 2.01
Decreased dependence of myelin basic protein-reactive T cells on CD28-mediated costimulation in multiple sclerosis patients. A marker of activated/memory T cells. J Clin Invest (1998) 1.99
Hydropathic anti-complementarity of amino acids based on the genetic code. Biochem Biophys Res Commun (1984) 1.77
Functional epistasis on a common MHC haplotype associated with multiple sclerosis. Nature (2006) 1.75
B-lymphoma cells process and present their endogenous immunoglobulin to major histocompatibility complex-restricted T cells. Proc Natl Acad Sci U S A (1989) 1.66
A sensitive method for detecting proliferation of rare autoantigen-specific human T cells. J Immunol Methods (2003) 1.59
Separable effector T cell populations specialized for B cell help or tissue inflammation. Nat Immunol (2001) 1.47
Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules. Eur J Immunol (1986) 1.39
Population of the HLA ligand database. Tissue Antigens (2003) 1.38
Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol (1994) 1.32
New genomic region for Wegener's granulomatosis as revealed by an extended association screen with 202 apoptosis-related genes. Hum Genet (2004) 1.29
Comparison of cytokine ELISpot assay formats for the detection of islet antigen autoreactive T cells. Report of the third immunology of diabetes society T-cell workshop. J Autoimmun (2003) 1.25
The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies. Nat Med (2004) 1.17
HLA antigen frequencies in systemic vasculitis: increase in HLA-DR2 in Wegener's granulomatosis. Arthritis Rheum (1983) 1.15
Association of Wegener's granulomatosis with HLA antigens and other genetic markers. Ann Rheum Dis (1992) 1.07
T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin Exp Immunol (1996) 1.05
T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener's granulomatosis (WG). Clin Exp Immunol (1994) 1.04
Idiotypic induction of autoimmunity: a new aspect of the idiotypic network. FASEB J (1994) 1.03
HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int (1992) 1.03
In vitro cytokine production and proliferation of T cells from patients with anti-proteinase 3- and antimyeloperoxidase-associated vasculitis, in response to proteinase 3 and myeloperoxidase. Arthritis Rheum (2002) 1.01
Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: epitope analysis using synthetic peptides. Kidney Int (2001) 0.99
T lymphocyte responses to anti-neutrophil cytoplasmic autoantibody (ANCA) antigens are present in patients with ANCA-associated systemic vasculitis and persist during disease remission. Clin Exp Immunol (1998) 0.97
Specific interactions between sense and complementary peptides: the basis for the proteomic code. Chembiochem (2002) 0.97
Characterization of the T-cell epitope that causes anti-GBM glomerulonephritis. Kidney Int (2005) 0.97
Resting small B cells present endogenous immunoglobulin variable-region determinants to idiotope-specific CD4(+) T cells in vivo. Eur J Immunol (1999) 0.96
Dendritic cells purified from myeloma are primed with tumor-specific antigen (idiotype) and activate CD4+ T cells. Proc Natl Acad Sci U S A (2000) 0.96
Auto-anti-idiotype: a basis for autoimmunity and a strategy for anti-receptor antibodies. Immunol Rev (1986) 0.96
Cell-mediated autoimmunity in patients with Wegener's granulomatosis (WG) Clin Exp Immunol (1995) 0.94
MHC-restricted Ig V region-driven T-B lymphocyte collaboration: B cell receptor ligation facilitates switch to IgG production. J Immunol (2004) 0.93
Immunogenetic risk factors for anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis. Clin Exp Immunol (1999) 0.92
HLA genes in ANCA-associated vasculitides. Exp Clin Immunogenet (1997) 0.90
[Specific selective interaction between amino acid groups of polypeptide chains]. Biofizika (1970) 0.90
New insights that link microbes with the generation of antineutrophil cytoplasmic autoantibodies: the theory of autoantigen complementarity. Curr Opin Nephrol Hypertens (2005) 0.88
Auto-anti-idiotypy, autoimmunity and some thoughts on the structure of internal images. Int Rev Immunol (1989) 0.86
Decreased frequency of HLA-DR13DR6 in Wegener's granulomatosis. Kidney Int (1995) 0.86
Translated anti-sense product of the Na/phosphate co-transporter (NaPi-II). Biochem J (1998) 0.85
Monoclonal antibodies to the thyrotropin receptor raised by an autoantiidiotypic protocol and their relationship to monoclonal autoantibodies from Graves' patients. Endocrinology (1988) 0.85
Production of antineutrophil cytoplasm antibodies derived from circulating B cells in patients with systemic vasculitis. Clin Exp Immunol (2003) 0.84
Role of complementary proteins in autoimmunity: an old idea re-emerges with new twists. Trends Immunol (2005) 0.83
In vitro T lymphocyte responses to proteinase 3 (PR3) and linear peptides of PR3 in patients with Wegener's granulomatosis (WG). Clin Exp Immunol (2000) 0.82
Ulcerative colitis in a renal transplant patient with previous Goodpasture disease. Pediatr Nephrol (2001) 0.82
On the specific mutual interaction of amino acid residues of polypeptide chains and amino acid residues with codons. Oncology (1973) 0.81
Leprosy in a high-prevalence Egyptian village: epidemiology and risk factors. Int J Dermatol (2002) 0.81
Making sense from antisense: a review of experimental data and developing ideas on sense--antisense peptide recognition. J Mol Recognit (1992) 0.81
Ligand receptor characteristics of peptides encoded by complementary nucleic acids: implications for a molecular recognition code. Recent Prog Horm Res (1988) 0.81
Frequency of proteinase 3 (PR3)-specific autoreactive T cells determined by cytokine flow cytometry in Wegener's granulomatosis. J Autoimmun (2004) 0.80
Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease. J Mol Med (Berl) (2004) 0.79
T cell help is required to induce idiotypic-anti-idiotypic autoantibody network after immunization with complementary epitope 289-308aa of La/SSB autoantigen in non-autoimmune mice. Clin Exp Immunol (2004) 0.79
What you should know about PR3-ANCA. Structural aspects of antibodies to proteinase 3 (PR3). Arthritis Res (2000) 0.79
The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int (2009) 7.45
The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol (2004) 7.38
The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int (2009) 7.19
Prevalence of chlamydial and gonococcal infections among young adults in the United States. JAMA (2004) 5.66
Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest (2002) 5.42
The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int (2004) 4.77
Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis (2004) 4.20
Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase. J Exp Med (2002) 3.83
Focal segmental glomerulosclerosis. N Engl J Med (2011) 3.77
Granulomatosis with polyangiitis (Wegener's): an alternative name for Wegener's granulomatosis. Arthritis Rheum (2011) 3.60
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Histopathologic classification of ANCA-associated glomerulonephritis. J Am Soc Nephrol (2010) 3.48
Predictors of relapse and treatment resistance in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis. Ann Intern Med (2005) 3.18
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells. AIDS (2008) 2.87
Autoimmunity is triggered by cPR-3(105-201), a protein complementary to human autoantigen proteinase-3. Nat Med (2003) 2.85
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. Proc Natl Acad Sci U S A (2007) 2.81
Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int (2011) 2.43
Association of histologic variants in FSGS clinical trial with presenting features and outcomes. Clin J Am Soc Nephrol (2012) 2.42
Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol (2007) 2.41
The prevalence of trichomoniasis in young adults in the United States. Sex Transm Dis (2005) 2.31
Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts. Arthritis Rheum (2008) 2.26
Discrepancy between Medical Evidence Form 2728 and renal biopsy for glomerular diseases. Clin J Am Soc Nephrol (2010) 2.25
Venous thromboembolism in patients with membranous nephropathy. Clin J Am Soc Nephrol (2011) 2.18
Classification of antineutrophil cytoplasmic autoantibody vasculitides: the role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis. Arthritis Rheum (2012) 2.17
Prevalence of HIV infection among young adults in the United States: results from the Add Health study. Am J Public Health (2006) 2.17
The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int (2010) 2.14
Pathogenesis of antineutrophil cytoplasmic autoantibody-associated small-vessel vasculitis. Annu Rev Pathol (2013) 2.02
Epitope specificity determines pathogenicity and detectability in ANCA-associated vasculitis. J Clin Invest (2013) 1.99
The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol (2005) 1.97
B lymphocyte depletion by CD20 monoclonal antibody prevents diabetes in nonobese diabetic mice despite isotype-specific differences in Fc gamma R effector functions. J Immunol (2008) 1.96
C5a receptor mediates neutrophil activation and ANCA-induced glomerulonephritis. J Am Soc Nephrol (2008) 1.92
Association between thyroid disease and its treatment with ANCA small-vessel vasculitis: a case-control study. Nephrol Dial Transplant (2007) 1.89
Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. J Clin Invest (2010) 1.87
An overview of glomerular filtration rate testing in dogs and cats. Vet J (2010) 1.87
Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol (2011) 1.82
Clinical trial to evaluate omega-3 fatty acids and alternate day prednisone in patients with IgA nephropathy: report from the Southwest Pediatric Nephrology Study Group. Clin J Am Soc Nephrol (2006) 1.76
Periodontal disease adversely affects the survival of patients with end-stage renal disease. Kidney Int (2009) 1.74
Apoptotic cells induce Mer tyrosine kinase-dependent blockade of NF-kappaB activation in dendritic cells. Blood (2006) 1.71
Patients with antineutrophil cytoplasmic antibody-associated vasculitis have defective Treg cell function exacerbated by the presence of a suppression-resistant effector cell population. Arthritis Rheum (2013) 1.70
Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int (2013) 1.69
Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha. Am J Pathol (2005) 1.65
Rituximab therapy for membranous nephropathy: a systematic review. Clin J Am Soc Nephrol (2009) 1.62
On the pathogenicity of autoantigen-specific T-cell receptors. Diabetes (2008) 1.61
Addendum to the International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments, and recommendations for testing in other autoimmune diseases. Am J Clin Pathol (2003) 1.61
SCreening for Occult REnal Disease (SCORED): a simple prediction model for chronic kidney disease. Arch Intern Med (2007) 1.56
The clinical course of ANCA small-vessel vasculitis on chronic dialysis. Kidney Int (2009) 1.54
Differential risk of remission and ESRD in childhood FSGS. Pediatr Nephrol (2006) 1.53
Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis. Am J Kidney Dis (2003) 1.53
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J Am Soc Nephrol (2011) 1.51
The preferential ability of B lymphocytes to act as diabetogenic APC in NOD mice depends on expression of self-antigen-specific immunoglobulin receptors. Eur J Immunol (2002) 1.50
Cutaneous and systemic manifestations of drug-induced vasculitis. Ann Pharmacother (2002) 1.48
Pathogenesis of vascular inflammation by anti-neutrophil cytoplasmic antibodies. J Am Soc Nephrol (2006) 1.48
Association of silica exposure with anti-neutrophil cytoplasmic autoantibody small-vessel vasculitis: a population-based, case-control study. Clin J Am Soc Nephrol (2007) 1.46
The effect of cholesterol reduction with cholestyramine on renal function. Am J Kidney Dis (2005) 1.46
Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci U S A (2004) 1.45
Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Invest (2006) 1.38
C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol (2013) 1.38
Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int (2010) 1.38
ANCA disease: where is this field heading? J Am Soc Nephrol (2010) 1.33